EUPATI

European Patients' Academy on Therapeutic Innovation
European Patients' Academy on Therapeutic Innovation

FACTS & FIGURES

Start Date
End Date
Call
IMI1 - Call 3
Grant agreement number
115334

Contributions
IMI Funding
5 250 000
EFPIA in kind
5 701 178
Other
0
Total Cost10 951 178

Summary

Medicines research and development (R&D) is an increasingly complex process that remains a mystery for the majority of patients and the general public. Lifting the lid on the medical R&D process is the IMI-funded EUPATI project. EUPATI is a patient-led initiative that aims to develop the first European Patients’ Academy on Therapeutic Innovation, with training courses, educational material and an online public library that will empower patients to engage more effectively in the development and approval of new treatments and become true partners in pharmaceutical R&D.

While patients are keen to have access to better and safer treatments, many find it hard to understand the benefits and risks of novel therapies. With demand for healthcare rising, and a growing emphasis on both the quality and sustainability of healthcare services, it is critical to address this major gap in public perception and knowledge.

There is therefore a proven need for information resources, designed specifically for patients and the public, on how medicines R&D and clinical trials are conducted. This should cover diverse aspects of pharmaceutical research and innovation, including translationalresearch and personalised and predictive medicine, as well as the ways in which patients can support the research process and contribute to therapeutic breakthroughs. Well-informed patients are not only better placed to understand and make decisions about their treatments, but can also help to put patients’ needs at the heart of drug development, for example by joining scientific, ethical and regulatory committees and getting involved in clinical trial design.

Power to the patients

The Patients’ Academy will produce comprehensive, scientifically reliable and user-friendly information for patients on all aspects of medicines development. It will increase the capacity and ability of well-informed patients and patients’ organisations to be effective advocates and advisors in medicines research.  The patient-led consortium, which includes patients’ organisations, academic groups, non-governmental organisations (NGOs) and pharmaceutical companies, will generate educational resources in six key areas, namely the medicines development process; personalised medicine; drug safety and risk/benefit assessments; health economics and health technology assessment; clinical trials; and patients’ roles and responsibilities in medicines development. Material will be developed in English, French, German, Italian, Polish, Russian, and Spanish. 

Objectivity, transparency and independence are essential if EUPATI is to achieve its goals. The project’s robust governance structure includes a multidisciplinary Project Advisory Board, a Regulatory Advisory Panel, and an Ethics Panel comprising renowned experts in bioethics, law, genetics, drug development, and patient advocacy, as well as representatives from regulatory authorities.

The project addresses three audiences. The ‘Expert Level’ will deliver a EUPATI Certificate Training Programme for patient experts, patient ambassadors and patient journalists. The accredited qualification will ensure that patients have the expertise and capacity to collaborate with all stakeholders involved in medicines R&D, wherever a strong patient voice is needed.

Advocacy leaders from patients’ organisations will be encouraged to access the ‘Education Level’ material in the EUPATI Toolbox. This will include a diverse range of cutting-edge resources such as e-learning courses, webinars, videos, slide shows for presentations, print material and face-to-face meetings.

Finally, all patients and the wider public will gain access to the EUPATI Internet Library, which will guide patients, including those with relatively low health literacy, through the complexities of the pharmaceutical R&D process.

Patients: industry’s partners in drug development

Involving patients in research can hugely benefit the drug development process; patients bring their own priorities and perspectives to the table and can offer fresh insights and challenge long-held beliefs, often resulting in entirely novel ideas and leading to better treatments for patients. Furthermore, greater patient involvement in R&D will boost the efficacy and safety of new treatments and raise public support for medical research.

Inducing a paradigm shift in patient involvement in medicines R&D

The Patients’ Academy is set to trigger a major rethink in the way patients and the public view the medicines development process and their own involvement in it. Armed with a deeper understanding of how the pharmaceutical sector works, patient experts and advocates will be empowered to work effectively with the relevant authorities, agencies, clinicians and industry to influence the drug development process for the benefit of patients. 

Achievements & News

EUPATI patient expert training course - applications open!
Applications are now open for the third cycle of the EUPATI Expert Training Course, which will run from September 2017 to December 2018. The course is an exciting and unique opportunity that offers patient advocates expert-level training in medicines research and development, ###specifically tailored for them. The course features a mix of online and face-to-face learning and includes modules on: discovery of medicines & planning of medicines development; non-clinical testing and pharmaceutical development; exploratory and confirmatory clinical development; clinical trials; regulatory affairs, medicinal product safety, pharmacovigilance and pharmacoepidemiology; health technology assessment principles and practices. The deadline for applications is 31 March 2017.
(February 2017)

EUPATI issues guidance on patient involvement in R&D
The EUPATI project has published a set of guidance documents to facilitate patient involvement in research and development (R&D). The documents focus on interactions between patients and regulatory agencies, health technology assessment (HTA) bodies, ethics committees and the pharmaceutical industry. ###The guidance documents suggest approaches to allow structured interaction with patient organisations on the national and European level and will support the integration of patient involvement across the entire process of medicines research and development. The guidance documents were developed on the basis of an extensive consultation with patient advocacy groups, regulators, pharmaceutical companies, HTA bodies, academic groups and clinicians, and incorporate feedback gathered during these reviews.
(January 2017)

EUPATI wants your views on patient involvement in R&D
Patient education project EUPATI has launched a public consultation to review the guidance it has developed on patient involvement in the medicines research and development process. ###The guidance is divided into four distinct frameworks:
 - patient involvement in industry-led R&D
 - patient involvement in health technology assessment (HTA) bodies
 - patient involvement in regulatory processes
 - patient involvement in ethics committees (to follow by end of July 2016)

They were developed in response to the growing need to draw on the experience and specific knowledge of patients, and their day-to-day use of medicines, in order to improve medicines development and evaluation. The frameworks suggest approaches to allow structured interaction with patients, and thereby facilitate the exchange of information and constructive dialogue at national and European level where the views from users of medicines can and should be considered. The four frameworks have already received feedback from a number of partners of the EUPATI consortium (including patient organisations), but further evaluation and feedback from patient organisations and other key stakeholders are essential in order to validate the guidance. Individuals and groups are invited to contribute to the review by commenting directly on the framework documents, which can be downloaded from the EUPATI website. The consultation will close on 15 September. (July 2016)

EUPATI conference 2016 - save the date!
IMI patient education project EUPATI will hold a conference entitled ‘EUPATI: All aboard to a better health future!’ on 14 December 2016 in Brussels, Belgium. ### More information will be published soon on the project website. To stay up to date with EUPATI’s activities:
- Sign up to their newsletter 
- Follow them on Twitter
- Like them on Facebook 

EUPATI launches educational toolbox on medicines R&D
IMI’s patient education project EUPATI has launched an online educational toolbox on medicines research and development (R&D). Designed for patients, patient groups, and anyone interested in learning more about medicines R&D, the freely-accessible toolbox includes materials covering drug discovery, clinical development, regulatory affairs, medicines safety, pharmacovigilance, and health technology assessment. ### The toolbox is available in seven languages: English, French, German, Spanish, Italian, Polish and Russian. It was designed by patients in collaboration with experts from other stakeholder groups such as academia and industry. Birgit Bauer, who has multiple sclerosis and recently graduated from the EUPATI Patient Expert course, welcomed the publication of the new website. ‘From my perspective, the EUPATI toolbox provides an objective, reliable and up-to-date resource for patient education on medicines R&D,’ she said. ‘The multilingual materials deliver a wealth of patient awareness materials and an understanding on the opportunities patient advocates have to strengthen their voice and to get actively involved in the process.’ The need for the new toolbox is backed up by recent EUPATI research which reveals that pharmaceutical industry personnel believe patients can improve medicines research and development. The study is published in the journal BMJ Open.
- Watch a video about the new toolbox. (January 2016) 

Save the date! EUPATI webinar on 16 November
The  European Patients‘ Academy on Therapeutic Innovation (EUPATI) will hold a webinar on ’Interaction between patients and other stakeholders in medicines development’ on 16 November 2015 from 17:00 to 18:30 Central European Time (CET). ###This webinar will focus on the interaction between patients and the other stakeholders active in the medicines development process. More information and details of how to register will follow shortly on their websiteEUPATI is a pan-European IMI project of 33 organisations, led by the European Patients' Forum, with partners from patient organisations, universities and not-for-profit organisations, along with a number of European pharmaceutical companies. The project focuses on education and training to improve the availability of patient-friendly information for the public as well as for more advanced patient advocates and patient experts with the capacity and capability to understand and contribute to medicines research and development. The project recently opened its second Patient Experts Training course and is looking forward to interacting with 60 highly-motivated people from more than 20 countries in Europe.
(October 2015)

EUPATI to hold webinar on patient involvement in HTA
July 2015 - Patient education project EUPATI will hold a webinar entitled 'Strengthening Patient Involvement in Health Technology Assessment (HTA)’ on 28 September ###at 17:00 CET (Central European Time). HTA is a multidisciplinary process that examines the information about medical, cost-effectiveness, social, political, legal and ethical considerations of the application of a health technology – usually a medicine, medical device or clinical/surgical procedure. The main purpose of such an assessment is to inform access policy decision-making, which has an impact on patients, physicians, payers and the broader health ecosystem. The webinar will examine the need for patient involvement in HTA and look at the HTA landscape in Europe. It will also feature a case study and a review of how the EUPATI toolkit can help informed patients engage in HTA. There will also be time to ask questions and engage in discussions.
 - Information on how to register can be found here

EUPATI training course: very successful interactive face-to-face meeting of trainees
April 2015 - EUPATI's Patient Expert Training Course educates patient advocates about the whole medicines research and development process over a period of 14 months. After six months of e-Learning, the first face-to-face part of the EUPATI course turned out to be a huge success. The five-day training event, ###held at the end of March in Barcelona, Spain, covered topics as diverse as medicines regulation, clinical trials, statistics, evidence, and ethics. It also featured "mock" ethics panel meetings and pharmacovigilance risk assessment meetings. The students have been following the course via distance learning since autumn 2014, and will continue to study this way until the second face-to-face training meeting in September. They will graduate in November 2015. The course is designed to provide patient advocates with the knowledge and skills to participate effectively in medicines research and development. ‘I am deeply impressed by this group of highly engaged patient advocates from 21 countries all across Europe, who are investing a significant share of their volunteer time over a period of more than a year to become knowledgeable patient experts in medicines R&D,’ commented EUPATI Director Jan Geissler. ‘The great spirit, the depth of discussions and the energy level every day was truly inspiring and is an amazing reflection of the power of patient advocacy.’ He added: ‘We are receiving lots of constructive feedback - very positive, as well as lots to learn from and improve for our next course, not surprising as this is a pioneer course - the first of its kind.’ Applications for the 2015/16 EUPATI course have now closed; the project received 187 applications for 60 places. The project is also developing a range of online information and educational materials for patients and patient advocates which will launch in seven languages by the end of 2015.

EUPATI paper in BMJ OPEN puts spotlight on public knowledge of medicines research
April 2015 - A research paper by IMI’s EUPATI project reveals that the majority of people in Europe (three quarters) have either no or ‘less than good’ knowledge of medicines research. However, people who have been involved in medical research themselves generally have much greater knowledge of medicines research. The findings, published in BMJ Open, are based on a survey of 7 000 people across Europe. The study also ###questioned participants on their interest in learning more about medicines research and development. The most popular areas (with around half of participants showing interest) were medicines safety, personalised medicine and predictive medicine. ‘We are all potential patents,’ said Kathy Oliver, Co-Chair of EUPATI’s Project Advisory Board and Chair of the International Brain Tumour Alliance. ‘This possibility emphasises the crucial need for the general public to really understand the numerous stages of medicines development and realise the complex processes that take place before a medicine is available for general use. EUPATI’s newly-published paper throws a fascinating light on what people already know about medicines research and development, and where the gaps are. In addition, the paper’s findings are of great value to us as patient advocacy groups because they validate the need for organisations like ours to help increase public knowledge and awareness about medicines research and development.’
- Read EUPATI’s press release

Join EUPATI for an interactive workshop on 22 April
March 2015 - Join the patient education project EUPATI in Dublin, Ireland on 22 April for the workshop  ‘EUPATI Taking off in Your Country – an Interactive Workshop on Implementing EUPATI in Your Country’. The project is in an exciting phase, ###as its training courses and materials are coming to life and going online.  The challenge for the project now is to spread the word to patient advocates, patient representatives, and patients, as well as to the project’s academic and industry partners, all at a more local level. The goal of the Dublin workshop is to help identify how to move forward on this, and participants will have an opportunity to discuss, together with consortium members, the current and future strategy for the implementation of EUPATI at the national level. The workshop is open to all stakeholder groups that have a role in the medicines development process - patients, citizens, industry, academia, ethics committees, regulators, medical professionals, journalists, etc. Participation in the workshop is free.
- For further details and registration, visit the event website

EUPATI Patient Expert Training Course – applications now open!
January 2015 - Applications are now open for the second round of the EUPATI Patient Expert Training Course, which offers 50 patients and patient advocates expert-level training in medicines research and development. ###The course features a mix of independent e-learning coursework and face-to-face training and will run for 14 months (from September 2015 to November 2016). By the end of the course, participants will have the knowledge needed to make meaningful contributions to patient empowerment and advocacy and to contribute to the broader dialogue on patient involvement in medicines research and development across Europe. The first round of the EUPATI Expert Training Course kicked off in October last year and will run until the end of 2015.
- Deadline for applications: 31 March 2015
- View the guide for applicants
Learn more about the EUPATI project

Did you miss EUPATI’s webinar on patient involvement in clinical research? Catch up online!
December 2014 - The slides and a recording from EUPATI’s first webinar on ‘Improving involvement of patients in clinical research’ are now available online.###During the 5 November event, representatives from patient organisations, universities and the pharmaceutical industry gave presentations on how to best include patients in clinical research, the advantages of patient involvement, and gave examples of patient research in their activities. The webinar also included discussions about challenges and barriers to patient involvement, as well as suggestions on how to overcome these issues. During the webinar, the outcome of EUPATI’s workshop held in July 2014 was also presented. The presentation provided information on efforts to demonstrate the benefits of patient involvement in R&D, implement a framework for patient involvement, and create relevant key performance indicators.

EUPATI patient course gets underway
October 2014 - IMI’s patient-led education and training project EUPATI has launched its first Expert Patient Training Course this October for 53 trainees from the patient community. EUPATI received more than 300 applications from patients and patient advocates wanting to take part, reflecting the demand from the patient community for in-depth training on the medicines research and development (R&D) process. ###The 15-month training course combines a blended learning approach of online and face-to-face training and covers all aspects of the medicines development process including discovery, development, evaluation, marketing authorisation and post-marketing evaluation. The e-learning platform provides a flexible way for the trainees to work progressively through the six modules, each kicking off with an introductory webinar. Expert tutors from the project will provide ongoing support throughout the course and there are two face-to-face training sessions planned in March and September 2015 to allow discussions about the relevant topics in small groups and in plenary sessions using case reports, news articles and samples of regulatory reports. A second training course for 50 additional trainees is planned for September 2015 and applications to participate should be made via EUPATI’s website in January 2015 when the selection process is opened. More details on the application process are available here. More information on the application process that applicants faced for the first selection can be found here.

Coming soon – the EUPATI e-learning website!
September 2014 - IMI’s patient education EUPATI is counting down to the launch of its e-learning platform in October. When launched, the platform will be used by the students who have been accepted onto EUPATI’s Expert Level training course. The platform is already up and running in beta and is currently populated with the learning materials for the Expert Patient online course. ###The layouts and navigation of the platform, which is built using open-source learning platform Moodle, have undergone testing by community users, and the online course materials are now undergoing a thorough review to verify both the information included and the teaching strategies used. The EUPATI Expert Training Course will combine online and face-to-face teaching to train patient experts in medicines development. The project received over 300 applications for the first course intake, of which only 55 could be admitted. Applications for next year’s course will open in Spring 2015.

EUPATI infographics reveal public attitudes to medicines development
June 2014 - EUPATI, IMI’s education and training project for patients and patient advocates, has recently published a series of infographics on its website summarising the results from its 2013 survey on ###the public’s knowledge, attitudes and understanding of medicines development. Over 7 000 members of the public from 6 EU countries took part in the survey.  
Participants rated their current knowledge on medicines development highest on those aspects relating to drug safety, discovery and clinical trials. Almost half of those who responded were interested in learning more about drug safety, personalised medicine and predictive medicine. According to the survey, people felt most comfortable asking for information about drug development from either medical staff or academic and patient organisations, and continue to look to their doctor, the internet and patient organisations as preferred sources of information about medicines research and development.

EUPATI workshop on patients’ involvement in medicines development
April 2014 - IMI’s Education and Training project EUPATI organised a workshop on 2 April in Warsaw, Poland. The event focused on the project’s efforts to increase the general public’s involvement in medicines’ research and development. ###Over 150 representatives of patient organisations, academia, industry and regulatory affairs met to discuss how to best increase the general public’s interest in these topics. The input from the workshop will shape EUPATI’s strategy to reach out to and inform at least 100 000 European citizens with interest in health.
EUPATI-sponsored research presented in Warsaw reveals low levels of knowledge of medicine development across Europe but a growing public interest in the area. Ideas and suggestions from the workshop will help to optimise the communications channels for the right audience.  Exploiting the growing potential of social media, and using messages that clearly demonstrate the connection between drug development and patient involvement are at the top of the list. EUPATI’s Internet Library, due to be launched towards the end of 2015, should further engage European patients in the process.
   -   For more information, read the Workshop press release
   -   Check out the presentations, videos and the Twitter wall of the workshop here


EUPATI training course – applications open
March 2014 - IMI’s education and training project EUPATI is launching an expert-level course  in medicines research and development specifically tailored for patients and patient representatives. The certificate course will begin in September 2014 and will be ###a mixture of online and face-to-face education modules over a 13-month period. Details of the subjects covered, the methodology, and the timelines can be found in the Guide for Applicants
   -   Deadline for applications: 20 April 2014.
   -   Apply for the course online
   -   For more information, check out the FAQ

EUPATI launches a catalogue of successful PPPs
February 2014 - IMI’s project European Patients’ Academy on Therapeutic Innovation (EUPATI) has created a catalogue of existing successful working models of public-private partnerships (PPPs) between patient organisations, the pharmaceutical industry and academia. The catalogue provides ###examples of successful cooperation, as well as information which can serve as inspiration for future PPPs keen to ensure the involvement of patients in medicines research and development. While not singling out any one model as the best for PPPs, EUPATI’s catalogue provides guidance for the establishment, terms and rules of new PPPs and how to track their progress.
   -   Check out EUPATI’s catalogue.
   -   Read the report detailing on the preparation and the methodology used to prepare the catalogue.

Meet the IMI Education and Training Programmes
December 2013 - There are five projects within IMI’s research training platform aiming to revolutionise education and training to deliver more effective and safe new medicines for patients – EMTRAIN, Eu2P, EUPATI, PharmaTrain, and SafeSciMET. Collaboration is the key to ###success and equally important is the projects' ability to reach intended audiences with information to raise awareness and encourage people to get involved in project activities. 
Over the next six months these projects will be represented at a variety of European and international conferences through display booths, dedicated sessions or individual presentations. If you are planning to attend any of the following events, please take the opportunity to stop by and find out what is happening in the IMI training and education programmes and how you can benefit, either from a professional or personal perspective. 
   - DIA EuroMeeting 2014  (Vienna, 25-27 March)
   - EUPATI Regional Meeting 2014  (Warsaw, 2-3 April)
   - World Research and Innovation Congress (Amsterdam, 5-6 June)
   - Euroscience Open Forum (Copenhagen, 21-26 June) 

Save the date for EUPATI
December 2013 - IMI’s EUPATI project (European Patients' Academy for Therapeutic Innovation) is organising a workshop entitled ‘EUPATI: Reaching the General Public on Medicines Development’ on 2 April 2014 in Warsaw, Poland. The event will address how to ###best inform patients, patient representatives and citizens, and raise public awareness of the development process of new medical treatments.
The EUPATI workshop is designed to discuss best practices on information sharing, seek input to help shape the EUPATI dissemination strategy and discuss sustainability options.
Above all, this event will be an opportunity to network with up to 150 patients, patient representatives and others to make a difference in connecting with and engaging patients, while helping EUPATI better understand the needs of local communities.
Participation in this workshop is free. Some grants will be available for participants from patient organisations and, in some cases, from academia, to cover travel and accommodation expenses.
Further information and registration details will be published shortly on the EUPATI website.

EUPATI Director wins outstanding leadership award
November 2013 - Patient advocate and EUPATI Project Director Jan Geissler has been presented with a European Outstanding Leadership Award ‘in recognition of his exceptional performance and leadership within EUPATI, in particular by addressing training issues and ###by improving the availability of both patient-centric information for the public as well as educating patient experts to have the capacity and capability to contribute to R&D’. The award, handed out annually by the Belgian Association of Clinical Research Professionals (ACRP), is presented to individuals who have demonstrated exceptional performance, achievement and sustained service towards the goals of ACRP and contributed to the advancement of clinical research in general. ‘I feel deeply honoured to accept this award on behalf of my fellow patient advocates as well as the EUPATI team,’ said Mr Geissler. ‘The fact that this award of research professionals is being bestowed on patient advocates, as well as to EUPATI, a partnership of patient organisations, academia and industry, is a reflection of the paradigm shift: patients are increasingly seen as true partners in medicines R&D.’

EUPATI needs your help in hunt for model partnerships
October 2013 - If you are aware of any examples of models of patients or patient organisations working successfully with clinicians, academia and /or the pharmaceutical industry, the EUPATI project would like to hear from you! The project is in the process of putting together a catalogue ###of successful models of these kinds of partnerships. The idea is to use the information to develop models to encourage the greater and more active involvement of patient experts in medicines research and development. By using extensive literature searches, surveys and an online feedback form, they have evaluated over 50 validated examples, but they hope to receive further examples by the end of this year. More information, and details of the survey and feedback form are available here.

EUPATI publishes draft training programme syllabus
July 2013 - Patient education project EUPATI has published the first version of the syllabus for its high-level certificate training course. EUPATI aims to ###educate patients to enable them to play a stronger role in medicines research and development, for example by contributing to the work of research groups and ethics and regulatory committees. The new syllabus sets out the training programme for the EUPATI certificate training programme, a 12-18 month course featuring face-to-face and online learning. The course’s six modules cover all aspects of drug development, including clinical trials, regulatory affairs, safety, and health technology assessment. The syllabus benefited from input from diverse stakeholder groups, including patients, academics, ethics experts, industry, and teachers. The courses are expected to start in 2014 and are designed for 100 patient experts.
In addition to the certificate, EUPATI is developing an educational toolbox that patient advocates can download and use to learn about drug development, and an internet library that will provide patients with easy-to-understand information on drug development.

EUPATI event looks to the future of patient involvement in research
April 2013 - On 19 April 2013, IMI project EUPATI held a public conference in Rome, Italy on a vision for patient involvement in medicines research in 2020. ###The conference brought together 183 participants from 28 countries. It was structured around three key questions:
   -   What would patient involvement in medicines development look like in 2020?
   -  How can we build knowledge & competences for patients' involvement in medicines R&D?
   -   By 2020, what increase can EUPATI predict in public knowledge about development of new treatments?
IMI’s EUPATI project aims at providing patients with training and education opportunities to enable them to play a role in the medicines R&D process. The conference unveiled EUPATI’s ongoing plans for three areas of training and education: a certificate level course that by 2017 will produce 100 patient experts drawn from across Europe; more generic online education for 10 000 patient representatives; and an Internet library providing information to anyone with an interest in medicines R&D. Attendees heard that the broad outlines of the content of courses and material have been established, but finding the right way of teaching them will prove more of a challenge – as will be selecting 100 people from across Europe for the certificate level course. Even translation can be challenging; for example, some languages do not have a term for ‘randomisation’. Overall, the tone of the meeting was positive, with many speakers noting that there is now a real window of opportunity for effective patient involvement in R&D.

BIOVISION and the IMI Education & Training projects
March 2013 - IMI and the IMI Education & Training projects participated in BIOVISION - the World Life Sciences Forum, which was held in Lyon, France, on March 24-26 2013. It is the place where key stakeholders ###debate the impact of the latest scientific advances on society and share their vision on how to overcome health, environment and nutrition challenges. IMI Executive Director Michel Goldman participated in the plenary session ‘How to make better use of collective intelligence’. Mike Hardman, project coordinator of EMTRAIN, represented IMI and the IMI E&T projects in the BIOVISION Investor Conference workshop. Moreover, the IMI E&T projects organised a satellite event on ‘Training and Education in Europe’ where they  presented their activities to the forum’s participants at a booth in the exhibition area.

IMI Education & Training projects in the spotlight at DIA EuroMeeting 2013
March 2013 - This year’s DIA EuroMeeting, which was held in Amsterdam, the Netherlands from 4 to 6 March, featured an entire theme dedicated to IMI’s five Education & Training (E&T) projects. The sessions featured ###the latest news from the projects and demonstrated how they are helping to advance education in the biomedical sector in Europe. DIA EuroMeeting visitors could also catch up with the projects and find out how IMI’s E&T projects can boost their careers.
 - View the agenda for the IMI theme in the DIA EuroMeeting programme  (page 46)

First EUPATI public workshop attracts over 100 participants
October 2012 - Over 100 people from 24 countries signed up to IMI Education & Training project EUPATI’s inaugural public workshop, which was held in Frankfurt, Germany in early September. ###The goal of the event was to gather feedback on the initial findings of the project, which aims to create a European Patients’ Academy on Therapeutic Innovation. ‘Nothing is set in stone,’ commented Project Coordinator Nicola Bedlington of the European Patients’ Forum. ‘We have a framework and clear ideas, but the input of all participants, being experts with different backgrounds and form different geographical areas, is absolutely vital to shape what we do. The floor is open.’ Items on the agenda in Frankfurt included how to raise awareness of EUPATI, how to establish national platforms, how to enhance the collection of information, and how to ensure that as many patients as possible benefit from the information generated by EUPATI. A full report of the workshop, as well as photos and webstreams from the workshops, are available from the project website.

Join the EUPATI Network
July 2012 - EUPATI (the European Patients’ Academy on Therapeutic Innovation) is inviting people to join the newly-created EUPATI Network. ###Open to patients and patient organisations, caregivers, academia, pharmaceutical & biotech companies, journalists, and anyone else interested in finding information on medicine research & development in lay language, the network offers members a number of benefits. In addition to information on EUPATI activities, events and networking opportunities, network members will also receive invitations to participate in EUPATI surveys or focus groups and will have the opportunity to collaborate with other network members, for example on the organisation of national events. Membership of the EUPATI Network is free of charge.

Participants Show participants on map

EFPIA companies
  • Amgen NV, Brussels, Belgium
  • AstraZeneca AB, Södertälje, Sweden
  • Bayer AG, Berlin, Germany
  • Boehringer Ingelheim International GmbH, Ingelheim, Germany
  • Bristol-Myers Squibb Company , Princeton, NJ, United States
  • Chiesi Farmaceutici S.p.A, Parma, Italy
  • Eli Lilly and Company Ltd, Basingstoke, United Kingdom
  • F. Hoffmann-La Roche Ltd, Basel, Switzerland
  • Glaxosmithkline Research And Development LTD, Brentford, Middlesex, United Kingdom
  • Janssen Pharmaceutica NV, Beerse, Belgium
  • Laboratorios del Dr Esteve, S.A., Barcelona, Spain
  • Merck KGaA, Darmstadt, Germany
  • Merck Sharp & Dohme Corp., Whitehouse Station, New Jersey, United States
  • Novartis Pharma AG, Basel, Switzerland
  • Novo Nordisk A/S, Bagsvaerd, Denmark
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sard, Chilly-Mazarin, France
  • The Employers' Union of Innovative Pharmaceutical Companies INFARMA (Związek Pracodawców Innowacyjnych Firm Farmaceutycznych), Warsaw, Poland
  • UCB Biopharma SPRL, Brussels, Belgium
  • Verband forschender Arzneimittelhersteller e.V., Berlin, Germany
Universities, research organisations, public bodies, non-profit groups
  • Asociacion Nacional Empresarial de la Industria Farmacéutica, Madrid, Spain
  • DIA Europe GmbH, Basel, Switzerland
  • European Forum for Good Clinical Practice, Brussels, Belgium
  • European Organisation for Research and Treatment of Cancer, Brussels, Belgium
  • Hibernia College, Dublin, Ireland
  • International Society for Pharmacoeconomics and Outcomes Research Inc, Lawrenceville, New Jersey, United States
  • Irish Platform for Patient's Organisations, Science and Industry, Dublin, Ireland
  • Københavns Universitet (University of Copenhagen), Copenhagen, Denmark
  • The University of Manchester, Manchester, United Kingdom
Patient organisations
  • European AIDS Treatment Group , Duesseldorf, Germany
  • European Genetic Alliance Network, Brussels, Belgium
  • European Organisation for Rare Diseases, Paris, France
  • Forum Europeen Des Patients - European Patients' Forum, Brussels, Belgium
Third parties
  • Genetic Alliance UK Ltd, 436 Essex Road, London, United Kingdom
  • Manchester University Hospitals Nhs Foundation Trust, Manchester, United Kingdom
  • Vereniging Samenwerkende Ouder- en Patiëntenorganisaties, Soest, Netherlands

CONTACT

Project coordinator
Jan Geissler
Verband forschender Arzneimittelhersteller e.V.
+32 2 2802334
jan[at]patvocates.net
Managing entity
Jan Geissler
Forum Des Patiens Europeens ASBL European Patients Forum FPE EPF
+32 2 2802334
jan[at]patvocates.net